Введение анти -VEGF препаратов в переднюю камеру глаза при вторичной неоваскулярной глаукоме

Abstract

For the purpose of reduction of newly formed vessels of the iris, reduction of intraocular pressure and preservation of the organ of vision, in the anterior chamber to 3 patients with secondary neovascular glaucoma was introduced 0,025 ml (0,25 mg) bevacizumab. The drug bevacizumab, introduced into the anterior chamber, did not cause any visible complications structures of the eye, leading to rapid disappearance of newly formed blood vessels in the iris and anterior chamber angle. Introduction to the anterior chamber of the eye to patients with neovascular glaucoma refractory promoted regression of neovascularization in the anterior segment of the eye, allowing effectively reduce IOP and preserve the eye.